EQT Is Paying 5.8 Times Sales for QIAGEN, a Company Whose Sales Peaked in 2021
QIAGEN agreed on October 21 to a €46.50-a-share takeover by EQT, about $12.1 billion including debt. Its filings show sales near $2 billion for four years, and a share price that had fallen below Thermo Fisher's failed 2020 offer.

On October 21, QIAGEN agreed to be taken private by EQT, the Swedish private equity firm, alongside co-investors from the Abu Dhabi Investment Authority and Canada's CPP Investments. The offer is €46.50 a share in cash. The companies value the deal at about €10.8 billion in enterprise value, or about $12.1 billion including roughly $1.1 billion of net debt. QIAGEN's boards recommend it, and closing is expected in mid-2027.
QIAGEN makes the kits that pull DNA and RNA out of samples, PCR and diagnostic tests, and, through QIAGEN Digital Insights, bioinformatics software such as variant interpretation tools. Its own filings show what EQT is buying.
What has happened to QIAGEN's sales?
QIAGEN sales jumped with the pandemic, peaked in 2021, and have stayed near $2 billion since.
QIAGEN annual net sales, US dollars (billions), 2016 to 2025.
- 12020: Thermo Fisher bids €39 a share
Source: QIAGEN annual reports on Form 20-F, via SEC XBRL company facts. Net sales as reported (revenue from contracts with customers). Not adjusted for currency or acquisitions.
View data
| year | sales |
|---|---|
| 2016 | 1.34 |
| 2017 | 1.42 |
| 2018 | 1.5 |
| 2019 | 1.53 |
| 2020 | 1.87 |
| 2021 | 2.25 |
| 2022 | 2.14 |
| 2023 | 1.97 |
| 2024 | 1.98 |
| 2025 | 2.09 |
Before the pandemic, sales grew slowly, about 4.5% a year from 2016 to 2019. During the pandemic they rose 47% in two years, to $2.25 billion in 2021. Since then they have fallen back and flattened: $1.97 billion in 2023, $1.98 billion in 2024 and $2.09 billion in 2025, still 7% below the peak.
At $12.1 billion, EQT is paying 5.8 times 2025 sales. That multiple is our arithmetic on the companies' figures; it uses the dollar value they quoted at current exchange rates.
How does the price compare with Thermo Fisher's 2020 bid?
In March 2020, Thermo Fisher announced an offer of €39 a share for QIAGEN. That attempt failed. EQT's €46.50 is 19% higher.
The more telling number is where the stock stood before this deal. The companies calculate their 40.3% premium from €33.15, QIAGEN's closing price on July 8, 2026, the last trading day before reports of private equity interest. That unaffected price was 15% below Thermo's offer of six years earlier. Sales were 37% higher in 2025 than in 2019, the last full year before Thermo's bid, but the market valued each share for less.
Where is the bioinformatics business in this?
QIAGEN calls QIAGEN Digital Insights one of its five growth "pillars". The 20-F does not report it separately. It sits inside the Genomics/NGS product group, which sold $241.8 million in 2025, 12% of the total and 3% more than in 2024. Consumables and related revenue, a category that includes the bioinformatics software, made up 90% of 2025 sales.
That makes the software a small part of a business built on recurring kit sales. Whatever EQT does with it, the price is not being set by bioinformatics.
Limits
The enterprise value and its dollar conversion are the companies' figures; we did not rebuild them. Comparing a per-share offer in 2020 with one in 2026 ignores changes in share count, debt and buybacks. The sales series is as reported and mixes organic growth, acquisitions and currency effects, and the COVID-related part of 2020 to 2022 sales is not separated in the data we used. The deal still needs at least 50% of shares tendered plus one share, and regulatory clearance.
Sources
- QIAGEN and EQT, joint press release on the takeover offer (German version), October 21, 2026, also filed with the SEC on Form 6-K, October 23, 2026: €46.50 per share, 40.3% premium to €33.15 on July 8, 2026, 46.9% premium to the three-month VWAP of €31.66, enterprise value of about €10.8 billion (about $12.1 billion including about $1.1 billion of net debt), closing expected mid-2027, 50% plus one share minimum acceptance.
- SEC, XBRL company facts for QIAGEN N.V.: annual net sales 2016 to 2025.
- QIAGEN, Annual report on Form 20-F for 2025: product group sales, Genomics/NGS at $241.8 million, consumables and related revenue at 90% of sales, QIAGEN Digital Insights as a growth pillar.
- Thermo Fisher Scientific, announcement of the decision to make a takeover offer for QIAGEN, March 3, 2020: €39 per share. Fierce Biotech, EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal: the 2020 attempt failed.
- Related: The exit moved: $130 billion of biotech acquisitions and a genome database was worth $6 billion and sold for $305 million.
Recommended Reading

The Exit Moved: $130 Billion of Biotech Acquisitions in Six Months, 11 IPOs in a Year

KRAS G12D Went From 2 Trial Starts to 24 in One Year. Now 17 of This Year's 20 Are Phase 2 or 3

Half of FDA's New Drugs Already Target Rare Diseases. The New Framework Aims at the Other 95%
Discussion (0)
Sign in to join the conversation and share your thoughts
No comments yet. Be the first to start the discussion!